Korsana Biosciences is moving to the public markets via a reverse merger with Cyclerion Therapeutics, bringing a large-scale financing package and a pipeline lead for Alzheimer’s disease. The merged company plans to operate under the Korsana brand and focus on KRSA-028, an amyloid-beta targeting monoclonal antibody designed to cross the blood-brain barrier. The transaction includes a reported $380 million private investment and is structured as an all-stock deal expected to complete in the third quarter. Korsana intends to initiate Phase 1 clinical testing with a target of reading out amyloid plaque clearance by the end of 2027. For investors and developers in neurodegeneration, the move underscores how biotech funding is increasingly tied to near-term biomarker endpoints and financing structures that support early clinical execution.